The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1617
February 8, 2021
View Complete Issue         Table of Contents 2019 
Osilodrostat (Isturisa) for Cushing's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Osilodrostat (Isturisa) for Cushing's Disease
February 8, 2021 (Issue: 1617)
The FDA has approved osilodrostat (Isturisa – Recordati), a cortisol synthesis inhibitor, for oral treatment of adults with Cushing's disease when surgical resection of the pituitary adenoma is not an option or has not been curative....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Osilodrostat (Isturisa) for Cushing's Disease
Article code: 1617c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.